SLU School of Science and Engineering Institute for Drug & Biotherapeutic Innovation SLUChemDept Saint Louis University #glycotime ACS_CARB

A publication from Saint Louis University's Susana Gonzalo reveals aging progression driven by non-canonical (cGAS-STING) inflammatory signaling. Blocking this pathway may be therapeutically promising for age-related disease. Read more here doi.org/10.1073/pnas.2… #drugdiscovery #progeria

Check out this recent publication for evidence-based expansion of access to HBV treatments in order to reduce incidence of liver damage, co-authored by IDBI Director John Tavis.

On World Hepatitis Day, read about the role RNAi interference can have on supporting a functional cure in chronic HBV infection in this review from SLU Medicine John Tavis and colleagues: doi.org/10.1126/scitra…

New from SLU School of Science and Engineering Scott Martin: fabrication of carbon electrodes into 3D printed microfluidic devices for flow analysis. Rapid prototyping, reproducible devices, and nanomolar neurotransmitter limits of detection are just some of the benefits. Read here: doi.org/10.1002/jssc.7…

The anti-cancer properties of natural product are at the center of a Ratna Ray lab publication from SLU Medicine. Momordicine-I shows inhibition of cancer growth in cell culture and mouse models, and reveal a modulatory role on tumor associated macrophages doi.org/10.3390/cancer…

Earlier this year SLU Medicine's John Tavis published on bi-modal Hepatitis B virus inhibitors that inhibit both capsid assembly and mature HBV DNA formation. This represents a new class of molecules with potential to cure HBV doi.org/10.1371/journa…

Repurposing approved drugs to treat neuropathic pain gains support in a publication from SLU Medicine Institute for Translational Neuroscience Daniela Salvemini. The S1PR1 antagonist Ozanimod mediates IFN-I related gene expression in two chronic pain models, suggesting a link to pain pathways doi.org/10.1097/j.pain…

📢Our latest publication on PAIN Journal is out!!!🤩 Intra-RVM delivery of ozanimod, S1PR1 antagonist, attenuates behavioral hypersensitivities by engaging noradrenergic/serotonergic inhibitory projections. SLU Department of Pharmacology & Physiology Institute for Translational Neuroscience SLU Medicine journals.lww.com/pain/abstract/…

Fathom is finally here! Thank you @NIH/NIGMS, High Q Technologies! Looking forward to exciting discoveries!

Get creative for a cause — the Rare Diseases Are Not Rare! 2025 Challenge Prize Competition launches on Sept. 15, 2025! Submit your artwork to help raise awareness about #RareDiseases, the people they affect & the need for research & development of treatment strategies for

Congratulations to SLU Medicine's Adriana Montano on a new NIH grant to study mechanisms, biomarkers, and potential therapies for mucopolysaccharidoses types I and IVA. In collaboration with Dr. Raymond Wang at Children's Hospital of Orange County, University of Minnesota, The University of Chicago, and University of Utah